Safety and immunogenicity of UB-612 heterologous booster in adults primed with mRNA, adenovirus, or inactivated COVID-19 vaccines: a randomized, active-controlled, Phase 3 trial.

Saved in:
Bibliographic Details
Title: Safety and immunogenicity of UB-612 heterologous booster in adults primed with mRNA, adenovirus, or inactivated COVID-19 vaccines: a randomized, active-controlled, Phase 3 trial.
Authors: Rumyantsev A; Vaxxinity, Inc., FL, USA., Wang L; Vaxxinity, Inc., FL, USA., Wang S; Vaxxinity, Inc., FL, USA., Kemp T; Vaxxinity, Inc., FL, USA., Wriggins A; Vaxxinity, Inc., FL, USA., Burks A; Vaxxinity, Inc., FL, USA., Fisher D; Vaxxinity, Inc., FL, USA., Brokke K; Vaxxinity, Inc., FL, USA., Fix A; Vaxxinity, Inc., FL, USA., Hensley S; Vaxxinity, Inc., FL, USA., Lewis M; Vaxxinity, Inc., FL, USA., Zhu R; AvanSight, Inc., CA, USA., Wang K; AvanSight, Inc., CA, USA., Shasha C; AvanSight, Inc., CA, USA., Piccini G; VisMederi srl, Siena, Italy., Manenti A; VisMederi srl, Siena, Italy., Montomoli E; VisMederi srl, Siena, Italy., DeAntonio R; Cevaxin, Panama City, Panama., Saez-Llorens X; Cevaxin, Panama City, Panama., Chan M; Cevaxin, Panama City, Panama., Alberto E; Health Index Multispecialty Clinic, Bacoor, Philippines., Lallaine Borra MD; St. Pauls Hospital, Iloilo, Philippines., Jaen AM; Iloilo Doctor's Hospital, Iloilo, Philippines., Heppner G; Vaxxinity, Inc., FL, USA., Palm U; Vaxxinity, Inc., FL, USA., Monath TP; Vaxxinity, Inc., FL, USA.
Source: EClinicalMedicine [EClinicalMedicine] 2025 Jul 21; Vol. 86, pp. 103349. Date of Electronic Publication: 2025 Jul 21 (Print Publication: 2025).
Publication Type: Journal Article
Journal Info: Publisher: The Lancet Country of Publication: England NLM ID: 101733727 Publication Model: eCollection Cited Medium: Internet ISSN: 2589-5370 (Electronic) Linking ISSN: 25895370 NLM ISO Abbreviation: EClinicalMedicine Subsets: PubMed not MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:2589-5370
DOI:10.1016/j.eclinm.2025.103349